fetching data ...

POS0247 (2024)
CIRCULATING CD4+CXCR5-PD-1hiICOS+ CELLS ARE ELEVATED INPATIENTS WITH NEWLY DIAGNOSED GIANT CELL ARTERITIS AND ASSOCIATE WITH THE CLINICAL OUTCOME
Keywords: Biomarkers, Adaptive immunity
M. E. Miranda-Carus1, B. Nieto-Carvalhal1, I. Monjo-Henry1, M. D. C. Uyaguari Morocho1, I. Casado-Juárez1, A. Balsa1, E. De Miguel1
1Hospital La Paz - IdiPAZ, Rheumatology, Madrid, Spain

Background: Giant cell arteritis (GCA) is a large-vessel granulomatous vasculitis [1,2]. It is characterized by the presence at the inflamed arterial walls, of activated PD-1+ CD4 T cells [1,2]; this contrasts with observations indicating that a defect of PD-1 signaling is implicated in the pathogenesis of GCA [2]. A population of CD4+CXCR5-PD-1 cells, termed Tph cells, has been described at the inflamed synovium and peripheral blood of patients with Rheumatoid Arthritis [3], and seem to play a pathogenic role in this condition [3].


Objectives: To study the frequencies of circulating total Tph (cTph) and activated ICOS+Tph (cICOS+Tph) cells in the peripheral blood of patients with newly diagnosed GCA (nGCA) and examine whether they are related with the clinical outcome.


Methods: This is a prospective non-interventional study performed on consecutive patients referred to our ultrasound (US) GCA fast track clinic, in whom newly diagnosed GCA (nGCA) was clinically confirmed (2022 ACR/EULAR criteria) over a period of 18 months. Peripheral blood was drawn immediately upon confirmation and after obtaining written informed consent. For each patient, an age and gender-matched healthy control (HC) was also studied. PBMCs isolated by Ficoll- Hypaque gradient were stained with antibodies to CD3, CD4, CD45RA, CD45RO, CXCR5, ICOS, PD-1, and examined by flow cytometry. Patients were treated with standard therapy according to clinical response.


Results: A total of 60 nGCA patients were included (mean age 82 years, 58 % female). As compared with HC, nGCA patients presented at baseline with an increased frequency of cTph and ICOS+cTph cells. Among the 37 patients who could be followed up for 12 months (the remaining 23 have been diagnosed less than 12 months ago), 15 (40.5%) experienced a relapse (2018 EULAR recommendations; symptoms plus: elevation of acute phase reactants and/or positive US). Interestingly, the baseline frequency of cTph and ICOS+cTph cells had been significantly lower in patients who relapsed as compared with those who did not.


Conclusion: Newly diagnosed GCA patients demonstrate an increased frequency of cTph and ICOS+cTph cells. Lower basal proportions of cTph and cICOS+cTph cells are associated with relapse.


REFERENCES: [1] Weyand CM, Berry GJ & Goronzy JJ. J Leukoc Biol. 2018.

[2] Zhang H, et al. Proc Natl Acad Sci U S A. 2017.

[3] Rao DA, et al. Nature. 2017.


Acknowledgements: NIL.


Disclosure of Interests: Maria-Eugenia Miranda-Carus Gebro Pharma, BMS, Beatriz Nieto-Carvalhal: None declared, Irene Monjo-Henry: None declared, Mariela del Carmen Uyaguari Morocho: None declared, Irene Casado-Juárez: None declared, Alejandro Balsa BMS, Eugenio De Miguel: None declared.


DOI: 10.1136/annrheumdis-2024-eular.2228
Keywords: Biomarkers, Adaptive immunity
Citation: , volume 83, supplement 1, year 2024, page 274
Session: Basic Poster Tours: New pathophysiological concepts of Vasculitis (Poster Tours)